Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity
Open Access
- 11 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 2 (8), e190
- https://doi.org/10.1038/cddis.2011.65
Abstract
Normal tissue damage limits the efficacy of anticancer therapy. For anthracyclines, the clinically most relevant adverse effect is cardiotoxicity. The mechanisms involved are poorly understood and putative cardioprotectants are controversially discussed. Here, we show that the lipid-lowering drug lovastatin protects rat H9c2 cardiomyoblasts from doxorubicin in vitro. Protection by lovastatin is related to inhibition of the Ras-homologous GTPase Rac1. It rests on a reduced formation of DNA double-strand breaks, resulting from the inhibition of topoisomerase II by doxorubicin. Doxorubicin transport and reactive oxygen species are not involved. Protection by lovastatin was confirmed in vivo. In mice, lovastatin mitigated acute doxorubicin-induced heart and liver damage as indicated by reduced mRNA levels of the pro-fibrotic cytokine connective tissue growth factor (CTGF) and pro-inflammatory cytokines, respectively. Lovastatin also protected from doxorubicin-provoked subacute cardiac damage as shown by lowered mRNA levels of CTGF and atrial natriuretic peptide. Increase in the serum concentration of troponin I and cardiac fibrosis following doxorubicin treatment were also reduced by lovastatin. Whereas protecting the heart from harmful doxorubicin effects, lovastatin augmented its anticancer efficacy in a mouse xenograft model with human sarcoma cells. These data show that statins lower the incidence of cardiac tissue injury after anthracycline treatment in a Rac1-dependent manner, without impairing the therapeutic efficacy.Keywords
This publication has 51 references indexed in Scilit:
- The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicityCardiovascular Research, 2006
- PLEIOTROPIC EFFECTS OF STATINSAnnual Review of Pharmacology and Toxicology, 2005
- Manganese superoxide dismutase and inducible nitric oxide synthase modify early oxidative events in acute Adriamycin-induced mitochondrial toxicityMolecular Cancer Therapeutics, 2005
- Dexrazoxane Protects against Myelosuppression from the DNA Cleavage–Enhancing Drugs Etoposide and Daunorubicin but not DoxorubicinClinical Cancer Research, 2005
- Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cellsCarcinogenesis: Integrative Cancer Research, 2005
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- ATM and DNA-PK Function Redundantly to Phosphorylate H2AX after Exposure to Ionizing RadiationCancer Research, 2004
- Detection of DNA Damage in Individual Cells by Analysis of Histone H2AX PhosphorylationMethods in Cell Biology, 2004
- Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells.1999
- Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53Oncogene, 1998